BACH PHARMA, INC. APPOINTS WILLIAM S. LYNN, MD AS LIFETIME DIRECTOR EMERITUS

North Andover, Massachusetts, USA (February 10, 2013) – During the February 2, 2013 Meeting of the Board of Directors of Bach Pharma, Inc. held in Durham, North Carolina, Chairman of the Board Dr. Steven L. Stroup announced the appointment of Dr. William S. Lynn of Hillsboro, North Carolina to the first ever position of Director Emeritus for the Company. Dr. Lynn has held the positions of Director, Vice President and Director of Science for Bach Pharma for the past 12 years. He continues to oversee the planning, design and reporting of all of Bach’s research and intellectual property. Dr. Lynn is a recognized thought leader in clinical research, with special emphasis in the areas of oxidative stress, inflammation, metabolism, neurodegeneration and the central nervous system. Dr. Lynn has written over 130 publications and books, and coined the term of his book titled “Neuroimmunodegeneration” with co-writer Dr. Paul K.Y. Wong in 1998.

Dr. Lynn received his undergraduate training in Alabama at Auburn University, and his MD degree at Columbia University in New York. He completed his postdoctoral fellowships at the University of Pennsylvania and Duke University. A Markle Scholar at Duke University, Dr. Lynn went on to become Professor of Medicine and Associate Professor of Biochemistry, where he became a lifelong enthusiastic fan of Duke Basketball. In 1992, after holding professorial positions at The University of Texas, Galveston, Departments of Internal Medicine and Human Nutrition, Dr. Lynn continued on to his current position of Visiting Scientist at the University of Texas, MD Anderson Cancer Center in Smithville, Texas.

Dr. Lynn has been a Clinical Research Physician at Cato Research in Durham, North Carolina since 1992, where he is responsible for managing the design, protocols, direction and interpretation of clinical trials and research from Phase 1 through Phase 4 of products under development. He has also coordinated reporting information to the FDA on adverse events and safety monitoring.

In his remarks to Dr. Lynn on the presentation of this award, Bach Pharma CEO, Mark O. Henry, detailed Dr. Lynn’s remarkable history and praised his work and integrity. “There is no one who knows more about oxidative stress in the human body,” he said. “Dr. Lynn’s knowledge has undoubtedly placed Bach Pharma in a leadership role in developing treatment for all manners of illness caused by oxidative stress. We are truly thankful for his association with our company and present him this award which confers a lifetime position on our Board of Directors.”

About Bach Pharma
Bach Pharma, Inc., based in North Andover, MA is a pharmaceutical company engaged in the discovery, development, and commercialization of new therapeutics for the treatment of life threatening oxidative stress related diseases as well as other serious illnesses. Bach is a member of the US-Russian Chamber of Commerce of New England and pioneered the founding of the US-Russian Scientific Exchange Forum. The Foundation for the National Institutes of Health (FNIH), in partnership with the National Institutes of Health (NIH), the Institute of Medicine (IOM) and the Russian Academy of Sciences (RAS) of the Russian Federation, was created as a result of the 2009 U.S.-Russia BiLateral Presidential Commission, which highlighted greater cooperation in the health sciences as a key theme. The Forum promotes and facilitates broader research collaboration in the biomedical and behavioral sciences between the U.S. and Russian scientific communities, with the goal of improving public health. Specifically, the Forum will strengthen joint research activities related to disease control, treatment and prevention, clinical and translational research, regulatory science, and the development of new health technologies.

Incorporated in 2001, Bach developed the proprietary manufacturing technologies for its proven phthalazinedione drug platform, and owns all of the intellectual property that encompasses this entire class of phthalazinediones as pharmaceutical agents. Monosodium Luminol is a subclass of phthalazinediones. Bach maintains one of the world’s most active monosodium luminol research programs focused on specific compound platforms and their derivates. Bach is an enthusiastic member of the MassBio Council, Advancing Massachusetts Biotechnology for worldwide medical benefits, and a proud host company of the Massachusetts Life Sciences Center Internship Challenge Program.

About Cato Research Ltd
Cato Research is a contract research organization (CRO) providing a complete range of services specializing in innovative development strategies for pharmaceutical and biotechnology companies through all stages of the clinical development process. Cato Research has strategic offices through-out the world, including Tel Aviv, Israel, Fourways, South Africa, and Quebec, Canada. Cato Research is a strategic alliance partner and CRO for Bach Pharma with offices located in the Bay Colony Corporate Center in Waltham, Massachusetts.

###

For more information about Cato Research companies please visit their main website www.cato.com, contact them by telephone 919.361.CATO (2286), or email info@cato.com. For additional information about Bach Pharma please visit their website at www.bachpharma.com, contact them by telephone 978.794.5510, or email info@bachpharma.com. For information about this press release please contact Dr. Norman Spencer at: normanspencer60@gmail.com.

Posted in Press Releases.